New reports on the South African strain of the coronavirus:
- Studies on the efficacy of current Pfizer vaccines should be available within 2 weeks
- It takes about 100 days to adapt the vaccine to a new variant (Pfizer)
- European Union points out that the new virus variant is a cause for concern
- European Commission is considering banning travel to and from countries where the new variant has been detected (some of these countries already canceled several flights to EU)
- The German Minister of Health points to the seriousness of the current situation
- Vaccine manufacturers' share prices rose sharply, stock indexes attempt to rebound, gold erased half of today's gains
As you can see, Friday's session, which was supposed to be boring due to low volatility, turned out to be completely different. We certainly won't get all the answers today, however it seems that the initial market reaction may have been exaggerated.
Daily Summary: Technology Drives Wall Street to Record Highs Despite Tensions in the Persian Gulf
Microsoft: Hedge Fund Sharply Cuts Position and Warns About AI Risks
🔴 Three markets to watch next week: EURUSD, CH50cash, OIL (08.05.2026)
Cloudflare: strong results, weak outlook, and a painful market reaction
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
